New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
06:33 EDTONCYOncolytics Biotech collaborators present head, neck cancer biomarker poster
Oncolytics Biotech announced that a poster authored by Bolton, et al was presented at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. The poster, titled "Resistance to oncolytic reovirus is associated with high expression of Yes-Associated Protein, or YAP-1, in head and neck cancer," covered preclinical research focused on identifying biomarkers predictive of sensitivity/resistance to reovirus in head and neck cancer cell lines. Researchers examined reovirus in panels of head and neck cancer cell lines to determine their sensitivity to reovirus-induced oncolysis. The study results showed that high YAP-1 protein expression correlated with reovirus resistance, whereas low YAP-1 expression correlated with sensitivity to reovirus infection. They also indicated that knocking the YAP-1 gene down resulted in certain cells becoming significantly more sensitive to reovirus infection. The researchers concluded that YAP-1 is a possible biomarker for sensitivity/resistance to reovirus infection in head and neck cancer and that further investigation into the crosstalk between chemical signaling pathways upstream and downstream of YAP-1 and its cellular localization, is important in understanding how it may be impeding reovirus oncolysis.
News For ONCY From The Last 14 Days
Check below for free stories on ONCY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
07:38 EDTONCYOncolytics Biotech price target lowered to $3 from $5 at RBC Capital
Subscribe for More Information
September 17, 2014
10:00 EDTONCYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:10 EDTONCYOncolytics Biotech downgraded to Hold from Buy at Stifel
Stifel downgraded Oncolytics Biotech to Hold citing disappointing topline results from its Phase II pancreatic cancer study.
September 16, 2014
17:09 EDTONCYOncolytics Biotech announces patient data from phase 2 study with REOLYSIN
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use